ARCH Venture Fund XII, L.P.

13D and 13G Filings

13D/G filings: 13D on 5 securities, 13G on 1 security
Location: Chicago, IL
CIK: 0001906837
Form D filings: 2 filings
All SEC filings: View on sec.gov

Issuer	Symbol	CUSIP	% of Class	Shares	Form	Filed
City Therapeutics, Inc. 13D 178782108		178782108	25.6%	13,692,507	13D	10/26/2026 Event 10/19/2026
ARCH Venture Fund XII, L.P.			25.6%	13,692,507
ARCH Venture Partners XII, L.P.			25.6%	13,692,507
ARCH Venture Partners XII, LLC			25.6%	13,692,507
Robert Nelsen			25.6%	13,692,507
Keith Crandell			25.6%	13,692,507
Kristina Burow			25.6%	13,692,507
Steven Gillis			25.6%	13,692,507
Parabilis Medicines, Inc. 13G PBLS · 698955101	PBLS	698955101	5.3%	6,412,780	13G	8/14/2026 Event 6/30/2026
ARCH Venture Fund XII, L.P.			5.3%	6,412,780
ARCH Venture Partners XII, L.P.			5.3%	6,412,780
ARCH Venture Partners XII, LLC			5.3%	6,412,780
Robert Nelsen			5.3%	6,412,780
Keith Crandell			5.3%	6,412,780
Kristina Burow			5.3%	6,412,780
Steven Gillis			5.3%	6,412,780
Seaport Therapeutics, Inc. 13D SPTX · 81221K108	SPTX	81221K108	11.9%	6,294,951	13D	5/6/2026 Event 5/4/2026
ARCH Venture Fund XII, L.P.			11.9%	6,294,951
ARCH Venture Partners XII, L.P.			11.9%	6,294,951
ARCH Venture Partners XII, LLC			11.9%	6,294,951
Robert Nelsen			11.9%	6,294,951
Keith Crandell			11.9%	6,294,951
Kristina Burow			11.9%	6,294,951
Steven Gillis			11.9%	6,294,951
Neumora Therapeutics, Inc. 13D/A Amendment 4 NMRA · 640979100	NMRA	640979100	18.7%	33,965,419	13D/A Amendment 4	4/1/2026 Event 3/30/2026
ARCH Venture Fund VII, L.P.			18.6%	33,847,838
ARCH Venture Fund VIII Overage, L.P.			18.6%	33,847,838
ARCH Venture Fund X, L.P.			18.6%	33,847,838
ARCH Venture Fund X Overage, L.P.			18.6%	33,847,838
ARCH Venture Fund XII, L.P.			18.6%	33,847,838
ARCH Venture Partners VII, L.P.			18.6%	33,847,838
ARCH Venture Partners X, L.P.			18.6%	33,847,838
ARCH Venture Partners X Overage, L.P.			18.6%	33,847,838
ARCH Venture Partners XII, L.P.			18.6%	33,847,838
ARCH Venture Partners VII, LLC			18.6%	33,847,838
ARCH Venture Partners VIII, LLC			18.6%	33,847,838
ARCH Venture Partners X, LLC			18.6%	33,847,838
ARCH Venture Partners XII, LLC			18.6%	33,847,838
Robert Nelsen			18.6%	33,847,838
Keith Crandell			18.6%	33,847,838
Clinton Bybee			2.0%	3,708,794
Kristina Burow			18.7%	33,965,419
Steven Gillis			17.3%	31,526,272
Metsera, Inc. 13D/A Amendment 1 MTSR · 59267L107	MTSR	59267L107	0%	0	13D/A Amendment 1	11/14/2025 Event 11/13/2025
ARCH Venture Fund XII, L.P.			0%	0
ARCH Venture Fund XIII, L.P.			0%	0
ARCH Venture Partners XII, L.P.			0%	0
ARCH Venture Partners XIII, L.P.			0%	0
ARCH Venture Partners XII, LLC			0%	0
ARCH Venture Partners XIII, LLC			0%	0
Robert Nelsen			0%	0
Keith Crandell			0%	0
Kristina Burow			0%	0
Steven Gillis			0%	0
Paul Berns			0%	0
Neumora Therapeutics, Inc. 13D/A Amendment 3 NMRA · 640979100	NMRA	640979100	20.7%	33,958,967	13D/A Amendment 3	10/29/2025 Event 10/27/2025
ARCH Venture Fund VII, L.P.			20.6%	33,847,838
ARCH Venture Fund VIII Overage, L.P.			20.6%	33,847,838
ARCH Venture Fund X, L.P.			20.6%	33,847,838
ARCH Venture Fund X Overage, L.P.			20.6%	33,847,838
ARCH Venture Fund XII, L.P.			20.6%	33,847,838
ARCH Venture Partners VII, L.P.			20.6%	33,847,838
ARCH Venture Partners X, L.P.			20.6%	33,847,838
ARCH Venture Partners X Overage, L.P.			20.6%	33,847,838
ARCH Venture Partners XII, L.P.			20.6%	33,847,838
ARCH Venture Partners VII, LLC			20.6%	33,847,838
ARCH Venture Partners VIII, LLC			20.6%	33,847,838
ARCH Venture Partners X, LLC			20.6%	33,847,838
ARCH Venture Partners XII, LLC			20.6%	33,847,838
Robert Nelsen			20.6%	33,847,838
Keith Crandell			20.6%	33,847,838
Clinton Bybee			2.3%	3,708,794
Kristina Burow			20.7%	33,958,967
Steven Gillis			19.2%	31,526,272
Prime Medicine, Inc. 13D/A Amendment 2 PRME · 74168J101	PRME	74168J101	10.4%	18,587,036	13D/A Amendment 2	8/11/2025 Event 8/7/2025
ARCH Venture Fund X, L.P.			10.4%	18,486,894
ARCH Venture Fund X Overage, L.P.			10.4%	18,486,894
ARCH Venture Fund XII, L.P.			10.4%	18,486,894
ARCH Venture Partners X, L.P.			10.4%	18,486,894
ARCH Venture Partners X Overage, L.P.			10.4%	18,486,894
ARCH Venture Partners XII, L.P.			10.4%	18,486,894
ARCH Venture Partners X, LLC			10.4%	18,486,894
ARCH Venture Partners XII, LLC			10.4%	18,486,894
Robert Nelsen			10.4%	18,587,036
Keith Crandell			10.4%	18,486,894
Kristina Burow			10.4%	18,486,894
Steven Gillis			10.4%	18,486,894
Metsera, Inc. 13D MTSR · 59267L107	MTSR	59267L107	25.5%	26,829,220	13D	2/10/2025 Event 2/3/2025
ARCH Venture Fund XII, L.P.			25.5%	26,816,808
ARCH Venture Partners XII, L.P.			25.5%	26,816,808
ARCH Venture Partners XII, LLC			25.5%	26,816,808
ARCH Venture Fund XIII, L.P.			25.5%	26,816,808
ARCH Venture Partners XIII, L.P.			25.5%	26,816,808
ARCH Venture Partners XIII, LLC			25.5%	26,816,808
Kristina Burow			25.5%	26,829,220
Keith Crandell			25.5%	26,816,808
Steven Gillis			25.5%	26,816,808
Robert Nelsen			25.5%	26,816,808
Paul Berns			8.8%	9,289,858

Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.